Provided by Tiger Trade Technology Pte. Ltd.

Ecopetrol SA

18.26
+0.52002.93%
Volume:1.35M
Turnover:24.60M
Market Cap:37.54B
PE:9.60
High:18.38
Open:17.68
Low:17.68
Close:17.74
52wk High:18.38
52wk Low:8.57
Shares:2.06B
Float Shares:237.00M
Volume Ratio:1.01
T/O Rate:0.57%
Dividend:0.99
Dividend Rate:5.43%
EPS(TTM):1.90
EPS(LYR):1.16
ROE:15.95%
ROA:7.31%
PB:1.83
PE(LYR):15.68

Loading ...

Press Release: Ecopetrol Reports Changes in Senior Management

Dow Jones
·
17 hours ago

Press Release: Updates to the Board of Directors of Ecopetrol S.A.

Dow Jones
·
18 hours ago

Ecopetrol Appoints Alfonso Camilo Barco Munoz as Acting CEO

MT Newswires Live
·
Yesterday

EU scrutiny of Anglo-MMG nickel deal tests China stance

Mining
·
Sep 11

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

GlobeNewswire
·
Sep 10

MMG faces EU antitrust warning over Anglo nickel deal

Mining
·
Sep 08

Press Release: Ecopetrol Announces Changes in Senior Management

Dow Jones
·
Sep 01

Press Release: Ecopetrol Announces Changes in Senior Management

Dow Jones
·
Aug 28

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

GlobeNewswire
·
Aug 24

EC Healthcare shareholders unanimously back AGM resolutions

TIPRANKS
·
Aug 21

Press Release: Ecopetrol Completes Acquisition of a Controlling 51% Stake in Brava Energia S.A. and Strengthens Its Growth Platform in Brazil

Dow Jones
·
Aug 18

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

GlobeNewswire
·
Aug 17

UBS Adjusts Ecopetrol Price Target to $16 From $14, Maintains Neutral Rating

MT Newswires Live
·
Aug 14

UBS Sticks to Their Hold Rating for Ecopetrol SA (EC)

TIPRANKS
·
Aug 14

Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Dow Jones
·
Aug 13

City Developments' Patmi triples in 1HFY2026; strategic review by end of Sept

The Edge Singapore
·
Aug 12

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

GlobeNewswire
·
Aug 11

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
Aug 05

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

GlobeNewswire
·
Aug 04

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

GlobeNewswire
·
Aug 04